News

Brussels, July 7, 2025 — The European Commission and PIC/S (Pharmaceutical Inspection Co-operation Scheme) have jointly released the draft “GMP Annex 22: Artificial Intelligence (AI)”, launching a ...

The U.S. Food and Drug Administration (FDA) recently issued an important announcement stating it will pause new clinical trial applications led by U.S. institutions that involve sending cells from U.S...

October 6, 2025 — San Francisco, USA – AstraZeneca announced a strategic collaboration and licensing agreement with Algen Biotechnologies, a U.S.-based biotech company specializing in AI-driven gene...

Researchers from University College London (UCL) and the University of Oxford have developed remote-controlled synthetic cells capable of delivering therapeutic proteins directly within the body. Thes...

Allogenica, a biotechnology company based in Lyon, has secured €2.5 million in funding from the French government’s France 2030 strategic investment program. The grant will accelerate the industrial...

The global cell and gene therapy market is projected to experience rapid growth over the next decade, reaching an estimated $39.61 billion by 2034, according to a recent report from Precedence Researc...

On September 22, 2025, Reuters reported that Bayer’s subsidiary BlueRock Therapeutics has officially initiated a Phase III clinical trial of its experimental stem cell therapy for Parkinson’s diseas...

Study Confirms Safety and Efficiency of Optimized K562 Feeder Cells for NK Cell ExpansionA new study published in the Annals of Laboratory Medicine (2025) has reported significant progress in the opti...

A new study published in BMC Biotechnology introduces an innovative engineered K562 feeder cell line (K562-4-1BBL-mbIL-21/IL-15) that has demonstrated remarkable performance in NK cell expansion. Rese...

Hillgene, a leading CDMO specializing in end-to-end solutions for viral vectors and cell therapies, is committed to supporting global partners with high-quality, scalable, and regulatory-compliant man...

Hillgene, a global CDMO specializing in end-to-end viral vector and cell therapy manufacturing solutions, is committed to advancing next-generation therapies through high-quality, scalable platforms. ...

The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for currently approved BCMA- and CD19-directed CAR-T therapies, the agency ann...